Novo Nordisk A/S (NVO) NYSE
36.98
+0.495(+1.36%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Novo Nordisk A/S
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
77406
First IPO Date
April 30, 1981
Key Executives
| Name | Title | Pay | Year Born |
| Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board | 0 | 1970 |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board | 1.92M | 1970 |
| Henrik Ehlers Wulff | Executive VP of CMC & Product Supply and Member of the Management Board | 2.03M | 1970 |
| Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board | 2.7M | 1971 |
| David S. Moore | Executive VP of US Operations & Member of Management Board | 0 | 1974 |
| Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board | 0 | 1975 |
| John F. Kuckelman | Group General Counsel | 0 | N/A |
| Ludovic Helfgott | Executive VP of Product & Portfolio Strategy and Member of Management Board | 0 | 1974 |
| Peter Hugreffe Ankersen | Corporate Vice President | 0 | N/A |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board | 0 | 1977 |
| Thilde Hummel Bogebjerg | Executive VP of Quality, IT & Environmental Affairs and Member of Management Board | 0 | N/A |
| Jacob Martin Wiborg Rode | Head of Investor Relations | 0 | N/A |
Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
